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Autosomal dominant hypophosphatemic rickets (ADHR) is unique
among the disorders involving Fibroblast growth factor 23 (FGF23)
because individuals with R176Q/W and R179Q/W mutations in the
FGF23 176RXXR179/S180 proteolytic cleavage motif can cycle from
unaffected status to delayed onset of disease. This onset may
occur in physiological states associated with iron deﬁciency, in-
cluding puberty and pregnancy. To test the role of iron status in
development of the ADHR phenotype, WT and R176Q-Fgf23
knock-in (ADHR) mice were placed on control or low-iron diets.
Both the WT and ADHR mice receiving low-iron diet had signiﬁ-
cantly elevated bone Fgf23 mRNA. WT mice on a low-iron diet
maintained normal serum intact Fgf23 and phosphate metabolism,
with elevated serum C-terminal Fgf23 fragments. In contrast, the
ADHRmice on the low-iron diet had elevated intact and C-terminal
Fgf23 with hypophosphatemic osteomalacia. We used in vitro iron
chelation to isolate the effects of iron deﬁciency on Fgf23 expres-
sion. We found that iron chelation in vitro resulted in a signiﬁcant
increase in Fgf23 mRNA that was dependent upon Mapk. Thus,
unlike other syndromes of elevated FGF23, our ﬁndings support
the concept that late-onset ADHR is the product of gene–environ-
ment interactions whereby the combined presence of an Fgf23-
stabilizing mutation and iron deﬁciency can lead to ADHR.
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Autosomal dominant hypophosphatemic rickets (ADHR,Online Mendelian Inheritance in Man no. 193100) is char-
acterized by low serum phosphate concentrations due to isolated
renal phosphate wasting, inappropriately normal or low serum
1,25(OH)2 vitamin D (1,25D) concentrations, and rickets/osteo-
malacia and fracture (1). Heterozygous missense mutations in the
ﬁbroblast growth factor-23 (FGF23) gene cause ADHR (2). These
mutations replace the arginine (R) residues at positions 176 or
179 with glutamine (Q) or tryptophan (W) within a 176RXXR179/
S180 subtilisin-like proprotein convertase (SPC) site that separates
the conserved FGF-like N-terminal domain from the variable C-
terminal tail (2–4). Acting through the coreceptor α-Klotho (5)
and a ﬁbroblast growth factor receptor (FGFR) (5, 6), FGF23
reduces renal phosphate reabsorption through down-regulation of
the sodium phosphate cotransporters NPT2a and NPT2c and
suppresses kidney 1,25(OH)2 vitamin D production by inhibiting
and increasing vitamin D 1α-hydroxylase (Cyp27b1) and 24-hy-
droxylase expression (Cyp24), respectively (7). Compared with
WT Fgf23 protein, ADHR-mutant FGF23 shows increased but
not complete resistance to SPC proteolytic cleavage (3, 4). When
expressed in mammalian cells, the R176Q-, R179Q-, and R179W-
FGF23 proteins are secreted primarily as the full-length (32-kDa)
polypeptide, in contrast to the full-length and cleavage products
(20 and 12 kDa) typically observed for WT FGF23 (3). This
proteolytic event inactivates the mature FGF23 polypeptide, as
full-length FGF23, but not N-terminal fragments (residues 25–
179) or C-terminal fragments (residues 180–251), reduces serum
phosphate concentrations when injected into rodents (4).
The ADHR biochemical and skeletal disease phenotypes
parallel those of other disorders of excess FGF23 including X-
linked hypophosphatemic rickets (XLH; loss-of-function muta-
tions in phosphate-regulating gene with homologies to endo-
peptidases on the X chromosome, PHEX), autosomal recessive
hypophosphatemic rickets (ARHR; loss-of-function mutations in
dentin matrix protein 1, DMP1) (8, 9), and the acquired disorder,
tumor-induced osteomalacia. ADHR was described ﬁrst in a
small family (10), and the subsequent analysis of an expanded
ADHR kindred demonstrated that, unlike XLH and ARHR,
ADHR displays incomplete penetrance and variable age of onset
(1), with elevated circulating intact FGF23 concentrations that
correlate with active disease status (11). ADHR contains two
subgroups of affected individuals: One subgroup consists of
patients who present during childhood with phosphate-wasting,
rickets, and lower limb deformity; the second subgroup consists
of phenotypic carrier individuals who are unaffected as children
but later present clinically during adolescence or adulthood (1).
Of signiﬁcance, female ADHR carriers can have late-onset dis-
ease during puberty and following pregnancy, both physiological
situations that are prone to iron deﬁciency (12), and male
ADHR patients also have shown disease onset and regression
over time (13). Further, reduced serum iron concentrations were
correlated strongly with increased serum FGF23 in ADHR
patients (14), and C-terminal FGF23 is negatively correlated
with ferritin (15); however, the mechanisms underlying these
observations are unknown.
Since late-onset ADHR can occur during physiological states
in which iron deﬁciency is common and reduced serum iron has
been associated with increased FGF23 concentrations in ADHR,
the goals of the present studies were to test the hypothesis that
an ADHR disease phenotype can be induced in a knock-in
R176Q-Fgf23 mouse model by decreasing iron load, and to de-
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termine the molecular mechanisms underlying FGF23 expres-
sion in bone during iron deﬁciency. The studies described here
have important therapeutic implications for rare and for more
common disorders of phosphate metabolism involving FGF23 by
providing a mechanistic basis for delayed onset of ADHR and
revealing unique cross-over regulation between phosphate and
iron metabolism.
Results
Murine Model Expressing an R176Q-Fgf23 ADHR Allele. A mouse
harboring an allele with an orthologous ADHR R176Q-Fgf23
mutation was developed using a knock-in strategy (Fig. S1 A and
B). Following targeting of the R176Q-Fgf23 construct and es-
tablishment of germline transmission of the mutant allele (Fig.
S1 A and B), RNA was isolated from heterozygous ADHR mice.
Using intron-spanning primers to amplify Fgf23 mRNA by RT-
PCR, appropriately-sized cDNAs were obtained and sequenced.
The ADHR-Fgf23 mRNA showed correct splicing for the three
exons, and the presence of the heterozygous knocked-in ADHR
R176Q mutation [codon cgc (Arg; R) >cag (Glu; Q) for mouse]
was conﬁrmed (Fig. S1C). No other substitutions were found in
the Fgf23 transcripts; thus these mice appropriately express
mRNA encoding the ADHR R176Q-Fgf23 mutant allele under
the native promoter and regulatory elements.
In Vivo Analysis of ADHR Onset and Progression: Mineral Metabolism.
Subjects with ADHR mutations are more likely to experience
late-onset disease during physiological states associated with low
iron status, therefore WT and ADHR mice were examined after
receiving diet with normal iron content (45 mg/kg iron; control
diet) or a low-iron diet (no added iron) from weaning (at 4 wk)
for an additional 8 and 12 wk (n = 6–12 male and female mice
per 8- and 12-wk cohorts). Similar diets and feeding periods have
been used previously to reduce iron status in rodents (16, 17).
Males and females were analyzed together, because there was no
interaction between the primary variables and sex. To isolate the
physiological effects of the mutant allele during iron deprivation,
homozygous R176Q-Fgf23 ADHR mice were tested initially (see
heterozygous ADHR results below). Although the male mice
were heavier than female mice, the mice on both diets gained
weight consistently over the treatment course (Fig. 1A).
To test the response of WT and ADHR mice to the low-iron
diet, we examined serum iron concentrations as well as a gene
that reliably adapts to iron status, the hepcidin antimicrobial
peptide (Hamp), which inhibits iron absorption from the small
intestine and is down-regulated during iron deﬁciency (18). Both
WT and ADHR mice provided the low-iron diet for 8 and 12 wk
had signiﬁcantly reduced total serum iron concentrations com-
pared with mice receiving the control diet (P < 0.01) (Fig. 1B).
The mice receiving the low-iron diets also displayed an appro-
priate decrease in liver hepcidin mRNA (P < 0.01; Fig. 1C).
Furthermore, WT and ADHR mice receiving the low-iron diet
showed changes consistent with iron-deﬁcient anemia in a com-
plete blood cell count (CBC), including signiﬁcantly reduced
mean corpuscular volume, mean corpuscular hemoglobin, and
increased red blood cell (RBC) distribution width, but no change
in total RBC number (Table S1). The markers of iron status
changed similarly in WT and ADHR mice, indicating that the
Fgf23 R176Q-ADHR allele did not markedly alter the normal
physiological responses to changes in dietary iron.
Next, to test the effects of iron deﬁciency in the context of the
ADHR R176Q-Fgf23 allele, serum biochemistries were evaluated
with regard to phosphate metabolism. At 8 wk serum phosphate
concentrations did not differ in WT and ADHR mice receiving
the control diet and WT mice fed the low-iron diet. In contrast to
these groups, the ADHR mice provided the low-iron diet were
signiﬁcantly hypophosphatemic (P < 0.0001 for diet effect in
ADHR and WT mice; Fig. 1D), and the hypophosphatemia per-
sisted at 12 wk (P < 0.001) (Fig. 1D). Serum calcium levels did not
differ among the groups (Fig. 1D). The ADHR mice receiving the
low-iron diet had signiﬁcant increases in alkaline phosphatase
(P < 0.01 for diet effect in ADHR and WT mice; Fig. 1D), and
alkaline phosphatase remained modestly elevated at 12 wk (P <
0.05; Fig. 1D). There were no signiﬁcant differences in para-
thyroid hormone (PTH) at 8 and 12 wk across genotypes and diets
(Fig. 1D). Serum creatinine was within the normal range (0.2–0.9
mg/dL) (8 wk: WT control/low-iron diet: 0.39 ± 0.04/0.4 ± 0.03;
ADHR control/low-iron diet: 0.30 ± 0.2/0.29 ± 0.02; 12 wk: WT
control/low-iron diet: 0.37 ± 0.04/0.39 ± 0.03; ADHR control/low-
iron diet: 0.39 ± 0.05/0.42 ± 0.03). Thus, mice carrying R176Q-
Fgf23 ADHR mutations and receiving the low-iron diet expressed
a biochemical phenotype that paralleled the clinical manifes-
tations of late-onset ADHR patients (1, 11).
Fgf23 Production and Processing in ADHR. Fgf23 can be detected in
the serum as intact, full-length Fgf23 or as circulating N- and C-
terminal fragments that arise from proteolytic cleavage of the
intact hormone at the 176RXXR179/S180 SPC site (3, 4). To test
the regulation of circulating Fgf23 protein following the re-
duction of iron status in the ADHR mice, we used two serum
assays, an “Intact Fgf23” ELISA that binds whole-molecule
Fgf23 and a “C-terminal Fgf23” ELISA that recognizes the full-
length protein and Fgf23 proteolytic fragments C-terminal to the
Fgf23 176RXXR179/ S180 SPC site. To test for changes in serum
Fgf23, subsets of WT and ADHR mice were assessed at 6 wk by
tail bleed and after mice were killed at 8 and 12 wk.
Intact Fgf23. Although there was a common age-dependent in-
crease, serum intact Fgf23 did not differ by diet in WT mice (Fig.
2A). In contrast, at 6 wk the proportion of abnormally high intact
Fgf23 (>161 pg/mL, 2.5 SD above the mean in the WT mice on
the control diet) differed among the four groups (P < 0.05):
Intact Fgf23 was abnormally high in 9 of 44 ADHR mice re-
ceiving the low-iron diet (cohort mean: 209.2 ± 59.1 pg/mL), in 2
of 31 ADHR mice on the control diet (cohort mean: 87.1 ± 7.9
pg/mL), and in 1 of 27 WT mice receiving the low-iron diet
(cohort mean: 92.1 ± 7.8 pg/mL) but was not elevated in any of
the 22 WT mice on the control diet (cohort mean: 78.7 ± 7 pg/
mL). At 8 wk, some of the ADHR mice on the low-iron diet also
manifested elevated intact Fgf23 (1,848, 1,770, 231, and 432 pg/
mL; up to 22-fold increase vs. control), whereas no WT mice had
values higher than twofold of the mean in these cohorts (n= 43).
At 12 wk, serum intact Fgf23 levels were signiﬁcantly lower in
ADHR mice receiving the low-iron diet than in the other groups
(P < 0.01), suggesting either down-regulation or altered Fgf23
processing during prolonged iron deﬁciency and hypophosphatemia
(Fig. 2A).
C-terminal Fgf23. To test whether iron status was associated with
Fgf23 proteolytic processing, we measured circulating Fgf23 us-
ing the C-terminal ELISA. C-terminal Fgf23 concentrations
were three- to sixfold higher on low-iron diets than on control
diets for both WT and ADHR mice (P < 0.0001; Fig. 2B). Im-
munoprecipitation of Fgf23 protein from bone lysates harvested
at 12 wk qualitatively revealed that only intact 32-kD Fgf23 was
detectable in the WT and ADHR mice receiving the control
diets (Fig. 2C). In contrast, the WT and ADHR mice receiving
the low-iron diets had increased immunoreactive Fgf23 and the
notable appearance of lower-molecular-weight Fgf23 protein
species (arrows and bracket in Fig. 2C).
We next examined the relationship between circulating intact
and C-terminal Fgf23 concentrations at 8 wk. The WT and
ADHR mice on the control diet showed a signiﬁcant (P <
0.0001) positive relationship between serum intact and C-ter-
minal Fgf23 (Fig. 2D, Left). Interestingly, the serum intact Fgf23
did not change with C-terminal Fgf23 in the WT mice receiving
the low-iron diet (Fig. 2D, Right) but increased signiﬁcantly in
ADHR mice (P < 0.001 for difference in slopes) (Fig. 2D, Right).
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This relationship was consistent with a reduced ability of the
ADHR mice to cleave the R176Q-Fgf23 protein species and
recognition by the C-terminal ELISA of a greater proportion of
circulating intact Fgf23 during iron deﬁciency.
In humans, the ADHR mutation presents as a dominant
phenotype; therefore we also tested the impact of iron deﬁciency
in heterozygous (Het) ADHR mice. The Het animals receiving
the low-iron diet had increased C-terminal Fgf23 after 8 and
12 wk of treatment (P < 0.0001; Table S2), normocalcemia with
modestly reduced serum phosphate (P < 0.01), and increased
serum alkaline phosphatase (P < 0.01). Although Het mice
carried both WT and ADHR alleles, intact Fgf23 was signiﬁ-
cantly reduced at 8 and 12 wk (suppressed 36% and 42%, re-
spectively; P < 0.01), possibly in response to the prevailing
hypophosphatemia. The biochemical manifestations were not as
severe in Het mice as in homozygous R176Q-Fgf23 ADHR mice,
suggesting a potential gene dosage effect of the mutant allele.
To test the mechanisms for the increased serum Fgf23 during
iron deﬁciency, Fgf23 mRNA concentrations in femur were ex-
amined by quantitative PCR (qPCR). At 8 wk, WT and ADHR
mice receiving the low-iron diet had signiﬁcant increases in Fgf23
mRNA, by 3.2- and sixfold (P < 0.001), respectively (Fig. 2E).
Fgf23 mRNA levels were increased further at 12 wk in WT mice
on the low-iron diet (P < 0.001), and the elevation was even
higher in ADHR mice on the low-iron diet (P < 0.05; Fig. 2E).
ADHR Skeletal Mineralization Phenotype. Although ADHR patients
develop rickets and osteomalacia (1), the phenotype of the
ADHR skeleton remains largely unknown. Histological analysis
of the distal femur using Goldner’s trichrome staining following
8 wk of treatment demonstrated that the WT mice on control and
low-iron diets and ADHR mice on the control diet showed nor-
mal bone, as assessed by measures of osteoid surface and thick-
ness (Fig. 3A), consistent with normophosphatemia in these
groups. In contrast, ADHR mice on the low-iron diet had ex-
tensive osteomalacia in the cancellous bone (Fig. 3A). Upon
analysis of cortical bone proximal to the metaphysis in ADHR
mice on the low-iron diet, we detected heterogeneous populations
of osteocytes: A portion of the cells appeared as osteocytic
lesions, surrounded by appreciable areas of osteoid (arrows in Fig.
3A). These cells were adjacent to areas containing osteocytes that
were indistinguishable from those in WT mice receiving either
control or low-iron diets and in ADHR mice receiving the control
diet (Fig. 3A). Quantiﬁcation of the defective mineralization
0
2
4
6
8
10
12
C
al
ci
um
 (m
g/
dL
)
0
2
4
6
8
10
12
P
ho
sp
ha
te
 (
m
g/
dL
)
0
50
100
150
200
250
A
lk
al
in
e 
P
ho
sp
ha
ta
se
 (
U
/L
)
0
10
20
30
40
50
60
70
P
TH
 (p
g/
dL
)
0
5
10
15
20
25
30
35
0 2 4 6 8 10 12
W
ei
gh
t (
g)
Weeks
Low M
Ctl. M
Low F
Ctl. F
0
5
10
15
20
25
30
35
0 2 4 6 8 10 12
W
ei
gh
t (
g)
Weeks
Low M
Ctl. M
Low F
Ctl.  F
WT
ADHR
1.0E-05
1.0E-04
1.0E-03
1.0E-02
1.0E-01
1.0E+00
H
am
p/
ac
tin
 m
R
N
A
(L
og
10
fo
ld
 
H
am
p/
ac
tin
 m
R
N
A
(L
og
10
fo
ld
 c
ha
ng
e)
0
50
100
150
200
250
To
ta
l s
er
um
 ir
on
 (µ
g/
dL
)
**
**
**
**
*
*
*
*
W
T 
Ct
l.
W
T 
Lo
w
AD
HR
 C
tl.
AD
HR
 L
ow
8 Week
W
T 
Ct
l.
W
T 
Lo
w
AD
HR
 C
tl.
AD
HR
 L
ow
12 Week
W
T 
Ct
l.
W
T 
Lo
w
AD
HR
 C
tl.
AD
HR
 L
ow
8 Week
W
T 
Ct
l.
W
T 
Lo
w
AD
HR
 C
tl.
AD
HR
 L
ow
12 Week
W
T 
Ct
l.
W
T 
Lo
w
AD
HR
 C
tl.
AD
HR
 L
ow
8 Week 12 Week
*
*
*
***
*** *
‡
W
T 
Ct
l.
W
T 
Lo
w
AD
HR
 C
tl.
AD
HR
 L
ow
8 Week
W
T 
Ct
l.
W
T 
Lo
w
AD
HR
 C
tl.
AD
HR
 L
ow
12 Week
W
T 
Ct
l.
W
T 
Lo
w
AD
HR
 C
tl.
AD
HR
 L
ow
8 Week
W
T 
Ct
l.
W
T 
Lo
w
AD
HR
 C
tl.
AD
HR
 L
ow
12 Week
W
T 
Ct
l.
W
T 
Lo
w
AD
HR
 C
tl.
AD
HR
 L
ow
8 Week
W
T 
Ct
l.
W
T 
Lo
w
AD
HR
 C
tl.
AD
HR
 L
ow
12 Week
W
T 
Ct
l.
W
T 
Lo
w
AD
HR
 C
tl.
AD
HR
 L
ow
A B C
D
Fig. 1. Mineral homeostasis in WT and ADHR mice. (A) Male (M) and female (F) WT and ADHR mice receiving control (Ctl; iron 45 mg/kg) and low-iron (Low;
iron 0 mg/kg) diets gained weight continuously over the time course (n = 5–10 mice per group). (B) The low-iron diet regimen resulted in signiﬁcantly reduced
total serum iron in the WT and ADHR low-iron groups (*P < 0.01; n = at least 4 mice per group). (C) qPCR of liver RNA showed reduced Hamp mRNA
concentrations at 8 and 12 wk in WT and ADHR mice provided low-iron diets (*P < 0.01; n = 5–10 mice per group). (D) Serum phosphate was reduced sig-
niﬁcantly at 8 and 12 wk of treatment in ADHR mice provided the low-iron diet compared with WT mice receiving control or low-iron diets and with ADHR
mice provided the control diet. Serum calcium was unchanged. Serum alkaline phosphatase was elevated in ADHR mice on the low-iron diet. PTH was not
different among groups (***P < 0.0001, **P < 0.001, *P < 0.01, ‡P < 0.05 vs. all groups; n = at least 12 mice per group).
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revealed that ADHR mice receiving the low-iron diet had a
ninefold increase in the percent of osteoid surface/bone surface
(OS/BS) compared with WT and ADHR mice provided the
control diet and WT mice receiving the low-iron diet (WT control
diet/WT low-iron diet/ADHR control diet: 6.17 ± 0.81%; ADHR
low-iron diet: 56.62 ± 10.71%; P < 0.05 vs. all groups) (Fig. 3B),
as well as increased osteoid thickness (P < 0.05) (Fig. 3B).
Renal Alterations in ADHR.To understand the molecular events that
resulted in the hypophosphatemic phenotype observed in the
ADHR mice, expression of genes regulated by Fgf23 was exam-
ined at 8 wk. There were no differences in the expression of the
type IIa sodium-phosphate cotransporter (Npt2a) protein between
WT and ADHR mice receiving the control diet and WT mice on
the low-iron diet. However, a marked reduction in Npt2a ex-
pression was observed in ADHR mice on the low-iron diet (Fig.
4A). Na/H exchange regulatory factor-1 (Nherf1), which delin-
eates the apical membrane, showed similar expression across diets
and genotypes (Fig. 4A, Inset). We previously determined that,
when delivered in vivo, Fgf23 initiates phospho-Erk1/2 (p-Erk1/2)
signaling within the kidney distal convoluted tubule, the primary
site of renal α-Klotho expression (19, 20). Using similar analysis of
ﬁxed kidney sections from control diet and low-iron diet cohorts,
only the ADHR mice receiving the low-iron diet showed strong
p-Erk1/2 staining that localized with Klotho (Fig. 4B).
Fgf23 is known to reduce circulating 1,25D concentrations
through transcriptional repression of the kidney anabolic enzyme
vitamin D 1-α-hydroxylase (Cyp27b1) and elevation of the cat-
abolic vitamin D 24-hydroxylase (Cyp24) (7). At 8 wk Cyp27b1
mRNA was 72.5 ± 8.9% reduced in ADHR mice receiving the
low-iron diet (P < 0.01; Fig. 4C, Upper). Cyp24 mRNA was in-
creased by 10.8 ± 2.13-fold in ADHR mice on the low-iron diet
(P < 0.01) Fig. 4C, Lower). Levels of Cyp27b1 and Cyp24 were
not signiﬁcantly decreased or increased, respectively, in WT mice
on either diet (Fig. 4C). Mice on the low-iron diet had reduced
serum 1,25D (ADHR: 58%, WT: 23%; P < 0.001), and the re-
duction was signiﬁcantly greater in ADHRmice (P < 0.05 vs. WT
low-iron diet) (Fig. 4C; Lower Inset).
Isolation of Fgf23 Regulation in Vitro. The osteoblastic cell line
UMR-106 expresses transferrin receptor-1 (TfRc1) and main-
tains saturable transferrin binding (21, 22). To test for direct
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Fig. 2. Fgf23 following dietary intervention. (A) Intact Fgf23: WT mice receiving control or low-iron diets showed no differences between groups in intact
Fgf23 at all time points. Fgf23 was elevated at 6 wk and reduced at 12 wk (*P < 0.01) in the ADHR mice on the low-iron diet. At 6 wk, the percentage of mice
with intact Fgf23 concentrations >2.5 SD the WT control diet group mean is listed above the intact Fgf23 concentration for each cohort (‡P < 0.05 for ADHR
mice on the low-iron diet v. all groups). (B) C-terminal Fgf23: C-terminal Fgf23 ELISA demonstrated signiﬁcantly elevated Fgf23 in all low-iron groups (***P <
0.0001). (C) Immunoprecipitation and Western blot analysis of Fgf23 from bone lysates at 12 wk revealed that, compared with the largely intact Fgf23 protein
produced by mice receiving the control diet, the low-iron diet resulted in increased immunoreactive Fgf23 proteolytic fragments in both WT and ADHR mice
(arrows and bracket). Actin in the starting lysates was used as the loading control, and the negative control with no primary antibody (Neg. Ab) resulted in no
immunoreactive protein. Molecular mass markers (M) are shown in kDa. (D) (Left) The intact/C-terminal Fgf23 concentrations showed a positive association in
WT and ADHR mice receiving the control diet (P < 0.0001). (Right) For the low-iron diet intact did not change with C-terminal Fgf23 in WT mice, but ADHR
mice had a positive correlation (P < 0.001 for difference in slopes). (E) Fgf23 transcripts were measured in total RNA from femur/tibia by qPCR. Transcript levels
were not different between WT and ADHR mice receiving the control diet for 8 or 12 wk. In mice provided the low-iron diet, Fgf23 mRNA was signiﬁcantly
increased in WT and ADHR mice at 8 and 12 wk [**P < 0.001; ‡P < 0.05 vs. WT mice on the low-iron diet; n = 6–14 mice (mixed sexes) per group].
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regulation of Fgf23 during iron deﬁciency in bone cells, UMR-
106 cells were treated with the therapeutic iron chelator defer-
oxamine (DFO) for 48 h. As expected, TfRc1 mRNA was in-
creased 10-fold by DFO treatment, conﬁrming the development
of low cellular iron (P < 0.05; Fig. 5A, Inset). Fgf23 mRNA was
increased signiﬁcantly, 12- and 20-fold, with 25 and 50 μM DFO
treatment, respectively (P < 0.01 each vs. vehicle control; Fig. 5A
Upper); these results are consistent with our ﬁndings on Fgf23
mRNA during iron deﬁciency in vivo (Fig. 2E). DFO has been
shown previously to increase Mapk activity (23). To test the role
of Mapk in the increase of Fgf23 production during iron de-
ﬁciency, UMR-106 cells were pretreated with the Mek1 inhibitor
U0126 (10 μM). Mitogen-activated protein kinase kinase-1
(MEK1) inhibition blocked the DFO-dependent rise in Fgf23
mRNA by more than 70% (U0126 data are shown in Fig. 5A; P <
0.05). DFO (25 and 50 μM, 48 h) signiﬁcantly increased p-Erk1/
2, and U0126 blunted this effect in UMR-106 cells (Fig. 5A,
Lower). To examine the molecular mechanisms for the elevated
Fgf23 mRNA under low-iron conditions, cells were treated with
L-mimosine (L-MIM; 50 μM), a speciﬁc egg-laying-defective nine
(EGLN) prolyl hydroxylase inhibitor that activates the hypoxia-
induced factor (HIF) transcription factors (24), key metabolic
sensors that control genes in response to iron deﬁciency in bone
and other tissues (25). Importantly, L-MIM produced a signiﬁ-
cant, time-dependent increase in Fgf23 mRNA (P < 0.01; Fig.
5B), and both DFO and L-MIM treatment resulted in stabiliza-
tion of HIF1α protein but not HIF2α in UMR-106 cells (Fig.
5C). To test whether the DFO- and L-MIM–dependent ele-
vations in Fgf23 mRNA were caused by increased transcription,
cells were pretreated with actinomycin D (0.1 μg/mL; 30 min),
followed by DFO or L-MIM for 24 h. Actinomycin D ablated
Fgf23 transcriptional activity with these agents (P < 0.05; Fig. 5D).
In summary, these studies determined that Fgf23 mRNA is
stimulated robustly in bone during iron deﬁciency in mice. WT
mice can counteract this response by proteolytically cleaving ex-
cess hormone at a secondary regulatory step to maintain stable
serum intact Fgf23 and normal serum phosphate. Our results
show that this proteolytic step is compromised in ADHR mice
carrying the R176Q-Fgf23 mutation, leading to increased serum
intact Fgf23, to alterations in genes controlling phosphate reab-
sorption and 1,25D production, and to hypophosphatemic bone
disease. Collectively, these ﬁndings support the notion that the
Fgf23 176RXXR179/S180 SPC site is central to controlling normal
blood concentrations of bioactive hormone. Furthermore, this
work demonstrates that, in the context of an ADHR R176Q-
Fgf23 mutation in mice, the induction of Fgf23 mRNA tran-
scription during iron deﬁciency has a stronger biological effect
than the combined suppressive actions of hypophosphatemia and
low 1,25D; these results are consistent with the inability of ADHR
patients to reduce serum FGF23 during late-onset, active disease.
Discussion
Here we provide evidence that late-onset ADHR, unlike other
disorders associated with elevated FGF23, is the product of gene–
environment interactions, whereby the presence of an ADHR
mutation and iron deﬁciency cause the disease phenotype. De-
creased serum total iron concentrations have been associated with
elevated FGF23 in ADHR patients (14), and our data support the
concept that during ﬂuctuations in serum iron, normal individuals
can control excess FGF23 through proteolytic processing via a
secondary regulation that maintains the concentration of serum
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magniﬁcation). (Middle) Enlarged images (20× magniﬁcation) of boxed areas in the top row demonstrated areas of intense osteomalacia in the ADHR low-
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intact FGF23. This identiﬁed regulatory step is likely compro-
mised in ADHR patients because of the mutations within the
FGF23 R176XXR179/S180 SPC cleavage site, which disrupt normal
proteolytic control of intact Fgf23 protein. When the biological
iron load was reduced through dietary intervention in ADHR
mice (Fig. 1 and Table S1), these animals demonstrated the
hallmark biochemical alterations associated with increased intact
Fgf23 secretion, including hypophosphatemia and inappropriately
reduced serum 1,25D concentrations, increased serum alkaline
phosphatase, and no signiﬁcant differences in serum PTH (Fig. 1).
These biochemistries are similar to observations from other mouse
models associated with increased circulating Fgf23, including the
Hyp mouse (26) and the ARHRmodel, the Dmp1-null mouse (8).
In contrast to these models, which show a fully penetrant phe-
notype from birth, similar to XLH and ARHR patients (8, 9, 27),
the ADHR disease phenotype associated with the R176Q-Fgf23
allele was induced through a stimulus of iron deﬁciency. Several
observations support the notion that the molecular etiology of the
active ADHR disease state is not solely the result of differences in
the ability of WT or ADHR mice to control iron status. In this
regard, the serum iron concentrations were similar in both WT
and ADHR mice receiving the control or low-iron diets at 8 and
12 wk (Fig. 1), and we observed the appropriate biological re-
sponses to iron deﬁciency in terms of genes that regulate iron
homeostasis and the development of iron deﬁciency anemia for
both genotypes (Fig. 1 and Table S1).
Excess FGF23 is associated with hypophosphatemia in ADHR
and other hypophosphatemic patients (11, 28–30) and in murine
models (8, 26, 31). We detected a signiﬁcant increase in serum
intact Fgf23 in the ADHRmice receiving the low-iron diet at 6 wk
and in a proportion of the ADHR mice at 8 wk. The normal or
increased levels of intact Fgf23 at 8 wk can be considered “in-
appropriate,” given the degree of hypophosphatemia (Fig. 1),
consistent with the stimulation of Fgf23 by a process external to
the classical Fgf23–phosphate endocrine axis, namely iron de-
ﬁciency. In WT mice provided the low-iron diet, as shown by
a combination of ELISAs that recognize intact and C-terminal
Fgf23 (Fig. 2), we determined that these animals produced in-
creased C-terminal fragments to maintain normal serum intact
Fgf23 and serum phosphate (Fig. 1) in the face of elevated Fgf23
mRNA (Fig. 2E). The inherently different physical-chemical
natures of the two assays and our current lack of knowledge of the
exact Fgf23 C-terminal fragment composition and turnover in
blood make it difﬁcult to calculate the absolute amount of C-
terminal FGF23. We therefore examined matched controls for
each diet, time point, and genotype to provide the appropriate
relative comparisons within the intact and C-terminal ELISA
results; taken together, these data strongly support the stabilizing
inﬂuence of the ADHR mutations in vivo. In addition, Western
blot analyses showed increased Fgf23 immunoreactive protein, as
well as lower-molecular-weight species in bone from the iron-de-
ﬁcient mice (Fig. 2C). These ﬁndings are in accord with a cellular
mechanism of ﬁrst producing intact Fgf23 and then subsequent
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Co
nt
ro
l
Lo
w
-ir
on
KL p-Erk1/2
10 µmK
L/
p-
Er
k1
/2
0
2
4
6
8
10
12
14
C
yp
24
/a
ct
in
 m
R
N
A
 (f
ol
d 
-0.95
-0.75
-0.55
-0.35
-0.15
0.05
0.25
Cy
p2
7b
1/
ac
tin
m
RN
A
(L
og
10
fo
ld
C
yp
27
b1
/a
ct
in
 m
R
N
A 
(L
og
10
fo
ld
 c
ha
ng
e)
C
yp
24
/a
ct
in
 m
R
N
A 
(fo
ld
 c
ha
ng
e)
*
*
WT
Control
WT
Low
ADHR
Control
ADHR
Low
WT
Control
WT
Low
ADHR
Control
ADHR
Low
10 µm
0
20
40
60
80
100
120
140
160
180
200
Se
ru
m
 1
,2
5D
 (p
m
ol
/L
)
W
T 
C
tl.
W
T 
Lo
w
AD
H
R
 C
tl.
AD
H
R
 L
ow
**
**
‡
WT
Control
WT
Low
ADHR
Control
ADHR
Low
A
B
C
Fig. 4. Molecular manifestations of ADHR in the kidney. (A) Immunoﬂuorescent analyses on ﬁxed kidney sections revealed that at 8 wk of dietary treatment
the ADHR mice on the low-iron diet (Lower Right; n = 4–6 mice per group) had detectable but reduced Npt2a (green) protein compared with WT mice
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(green), whereas ADHR mice on the low-iron diet showed increased p-Erk1/2 activity (red) that localized with Klotho. (C) qPCR analyses demonstrated
suppression of Cyp27b1 (Upper) and increased expression of Cyp24 (Lower) mRNAs in the ADHR low-iron cohort compared with the other groups. For
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proteolytic cleavage. Whether these lower-molecular-mass species
represent forms of Fgf23 with differing O-glycosylation (4) and
proteolytic cleavage fragments (including additional endoproteo-
lytic cleavage sites beyond the known 176RXXR179/S180 SPC site) or
combinations of these potential regulatory processes remains to
be determined.
Previous studies indicated that injection of the Fgf23 N- and C-
terminal proteolytic fragments had no effect on serum phosphate
concentrations, whereas delivery of whole-molecule Fgf23 was ca-
pable of reducing serum phosphate (4). In agreement with this
prior work, although serum C-terminal fragments were increased
signiﬁcantly in the WT and ADHR animals receiving the low-iron
diet (Fig. 2), we detected no difference in the serum phosphate
levels (Fig. 1D) or bone osteomalacia (Fig. 3) in WT animals re-
ceiving the control or low-iron diets or in ADHR animals provided
control diets. At this time, we cannot rule out the possibility that
R176Q-Fgf23 undergoes additional processing in vivo at domains
other than the 176RXXR179/S180 SPC site or inactivation by other
mechanisms during chronic Fgf23 mRNA up-regulation. It is likely
that combinations of these effects may be present in some ADHR
patients during disease onset and progression and might reﬂect the
variable metabolic bone and biochemical phenotypes associated
with this disorder (1). Although we determined that the R176XXR179/
S180 SPC site in Fgf23 is necessary for regulating circulating in-
tact Fgf23 concentrations (at least under low-iron conditions),
the sensing mechanisms that communicate the biological con-
ditions under which Fgf23 should be cleaved actively remain to
be determined. The SPC enzyme responsible for FGF23 pro-
cessing also is currently unknown; however, SPC2 and its co-
factor 7B2 recently have been associated with FGF23 proteolysis
(32). The fact that ADHR mice were hypophosphatemic with
normal or suppressed serum intact Fgf23 following a low-iron
diet (Fig. 2) could indicate that the combined actions of Fgf23
proteolysis and potential renal compensatory mechanisms at the
level of its signaling complex cannot completely abolish Fgf23-
dependent bioactivity. Whether this reduction in intact Fgf23 in
the face of elevated Fgf23 mRNA is speciﬁc for iron-deﬁcient
states remains to be determined. Of signiﬁcance, these obser-
vations in ADHR mice parallel those in a subset of hypo-
phosphatemic ADHR patients who had inappropriately normal
serum FGF23 (11). Further, the inﬂuence of other factors, in-
cluding sex steroids, on iron deﬁciency-dependent Fgf23 ex-
pression and processing are unknown.
Mice up-regulate Npt2a (33) and Cyp27b1 and down-regulate
Cyp24 (34) during diet-induced hypophosphatemia. In line with
the known in vivo effects of Fgf23, we detected a marked de-
crease of Npt2a in ADHR mice on the low-iron diet (Fig. 4A)
(31), with suppressed Cyp27b1 and elevated Cyp24 (Fig. 4C)
corresponding to the inappropriately low 1,25D (Fig. 4C, Inset).
We also detected a modest decrease in serum 1,25D in WT mice
provided the low-iron diet at 8 wk (Fig. 4C, Inset). In WT mice
this decrease coincided with a slight increase in serum intact
Fgf23 at the same time point (Fig. 2A). Given that, when injected
in vivo, Fgf23 affects 1,25D production more potently than se-
rum phosphate production (35), this decrease could indicate a
partial ”leakiness” of intact Fgf23 proteolytic processing in the
face of signiﬁcantly elevated Fgf23 mRNA (Fig. 2E). Consistent
with the hypophosphatemia in the ADHR mice receiving the
low-iron diet, these mice presented with marked osteomalacia
and osteocytic lesions (Fig. 3), which also are apparent in bone
from Hyp mice and XLH patients (36).
The endocrine relationships between serum iron, phosphate,
1,25D, and Fgf23 are likely complex. Of note, medications such
as infusions of select iron-containing compounds increase serum
FGF23 concentrations, with patients developing hypophospha-
temia and decreased serum 1,25D (37–39). In ADHR patients,
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however, low serum iron was correlated with elevated serum
FGF23 concentrations (14), and mice fed a low-iron diet up-
regulate serum Fgf23 (Fig. 2B) and bone Fgf23 mRNA (Fig. 2E),
a result that appears converse to the aforementioned case
reports involving iron infusion. The physiological reasons for this
divergence are currently unknown; however, it is noteworthy that
in the clinical reports both saccharated ferric oxide and iron-
polymaltose infusion caused an elevation of FGF23, but dextrin-
iron infusions did not (39–41). Thus, the difference in the ki-
netics of iron release from these pharmacological preparations
or a rapid increase of iron may affect FGF23 expression differently
than the long-term, physiologic regulation of iron in humans
during normal variations in puberty or pregnancy or than the
changes in dietary iron intake over weeks in mice during alter-
ations in dietary iron exposure. Collectively, our work suggests that
the ADHR phenotype may be controlled by administration of
some forms of iron.
Our in vitro results demonstrated that decreasing free iron by
DFO chelation and the activation of the HIF1α transcription
factor using the EGLN inhibitor L-MIM (Fig. 5) (24) resulted in
increased Fgf23 mRNA (Fig. 5). Further, Fgf23 transcription
following DFO and L-MIM treatment was abolished by actino-
mycin D, indicating that Fgf23 was up-regulated by these agents
through enhanced transcription (Fig. 5). In support of HIF ac-
tivation in vivo, hepcidin, a direct target of HIF activity (42), was
suppressed markedly by a low-iron diet in both WT and ADHR
mice (Fig. 1). These ﬁndings support a model whereby iron de-
ﬁciency results in stimulation of HIF1α, leading to increased
Fgf23 transcription; however, whether HIFs directly or indirectly
control Fgf23 remains to be determined. The physiological basis
for the control of Fgf23 by iron deﬁciency through HIF regula-
tion is unclear currently, although there are known biological
associations between iron and phosphate homeostasis. In this
regard, iron is contained within the hydrophilic core of the car-
rier protein ferritin as ferric hydroxide-phosphate complexes.
Kinetic studies show that the ferritin iron-loading process is 10-
fold more efﬁcient in the presence of phosphate ions than in the
presence of other anions such as nitrate and carbonate (43);
therefore maintaining overall phosphate balance through Fgf23
potentially could inﬂuence iron storage. Certainly, additional
studies will be required to test and expand our understanding of
these speciﬁc biological interactions.
In sum, our ﬁndings indicate that ADHR is a disease produced
through gene–environment interactions. We demonstrated that
Fgf23 mRNA is up-regulated in bone in mice during iron de-
ﬁciency, and in the context of an ADHR R176Q-Fgf23 allele this
biological situation leads to elevated intact Fgf23 and to hypo-
phosphatemic bone disease. Further, although elevated in WT
mice during iron deﬁciency, native Fgf23 protein is proteolytically
cleaved to maintain stable serum intact Fgf23 and phosphate.
These results provide a mechanistic link between iron and phos-
phate homeostasis that explains the clinical phenotype of ADHR
and may reveal therapeutic targets for both rare and more com-
mon disorders of phosphate handling and biomineralization.
Materials and Methods
Animal Studies. Animal studies were performed according to the Institutional
Animal Care and Use Committee (IACUC) for Indiana University and comply
with National Institutes of Health guidelines for the use of animals. All ES cell
procedures and initial test breeding for ADHR knock-in animal production
were undertaken with IACUC approval by the Indiana University Transgenic
Facility according to their standard protocols.
Gene Targeting to Create the R176Q-Fgf23 ADHR Allele. To derive a mouse
model with control of an R176Q-Fgf23 ADHR mutant allele under the native
Fgf23 5′ promoter and regulatory elements, a knock-in strategy was used. A
targeting construct for homologous recombination at the Fgf23 locus was
developed by isolating an 11-kb fragment of the murine 129/SvJ strain Fgf23
gene containing exons 2 and 3 as an Xba/SacI fragment. This Fgf23 129-
strain clone (a generous gift of Beate Lanske, Harvard University, Cam-
bridge, MA) was used to make an Fgf23-null mouse (44) and was subcloned
into pBluescript(SK+) (pBSK). The neomycin resistance gene (Neor) ﬂanked
by LoxP sites was removed from the pBSK-PGKneoLox2 vector (the generous
gift of Fred Dick, University of Ottawa, Ottawa) using an EcoRV-SmaI digest
(New England Biolabs, Inc.) and was ligated in the forward direction into
a Bstz17I (New England Biolabs, Inc) site in Fgf23 intron 2 (Fig. S1A).
The R176Q-Fgf23 ADHR mutation (from nt 528cgc530–528cag530)
and a silent SacI site 3′ to the R176Q mutation (from nt 627gagctG632–
627gagctC632) were directed to the AatII-SbfI fragment of Fgf23 exon 3
using PCR with complementary primers containing the mutated nucleotides
in the center position and the high-ﬁdelity polymerase PfU (Agilent Tech-
nologies). The silent SacI site provided the ability to test for recombination
of the ADHR allele (Fig. S1A). The coding region of the targeting construct
was sequenced to ensure no cloning gaps or mutations in the intron–exon
junctions. Once sequenced, the construct also was submitted to in vitro Cre
recombination using the 294-Cre Escherichia coli (stably integrated Cre;
Clone #47071; American Type Tissue Collection) which resulted in successful
removal of the ﬂoxed Neor cassette. Transfection of the construct into 129/
SvJ-strain ES cells was performed by the Indiana University Transgenic Fa-
cility staff according to standard electroporation protocols. Recombinant
cells were selected in G418, and DNA lysates (Gentra Systems) from resistant
colonies were screened by Southern blot analysis using SacI digests and a 3′
external probe as well as a Neor probe (Fig. S1A), according to standard
protocols. The ES cells showed correct homologous recombination for the
R176Q-Fgf23 allele within an expected 1–2% efﬁciency (Fig. S1A).
After ES cell implantation and derivation of 129/SvJ/C57Bl6 chimeric mice,
chimeric male mice with high ES cell contribution were backcrossed to C57BL/
6 females; germ line transmission was predicted by coat color and conﬁrmed
by Southern blot analysis of genomic tail-clip DNA (Fig. S1A). The hetero-
zygous ADHR mice carrying the Neor cassette (Fig. S1A) then were mated to
the ubiquitously expressed EIIa-Cre transgenic mice (Jackson Laboratory) to
remove the ﬂoxed Neor gene from Fgf23 intron 2 in vivo. The deletion of the
Neor gene through this mating was conﬁrmed by the fact that the PCR
products spanning the intronic site carrying Neor migrate more slowly by
electrophoresis than the same genomic position in WT DNA because of the
presence of the remaining LoxP site (Fig. S1B) and also was conﬁrmed by
DNA sequencing. Genotyping was performed with PCR primers that span the
LoxP site remaining from Cre recombination of the Neor gene and primers
that span the ADHR-R176Q Fgf23 mutation (Fig. S1B). All studies were
performed on WT and ADHR generation N10 mice backcrossed to C57Bl6.
Rodent Diets. The experimental diets were obtained from Research Diets, Inc.
The control diet was the standard AIN-76A base diet with the S10001 mineral
mix containing iron at a concentration of 45 mg Fe/kg (carbonyl iron). The
iron-deﬁcient diet was the AIN-76A base diet and S10001 mineral mix with
the iron removed (∼0.1 ppm iron ﬁnal concentration). All diets contained
customary 0.55% phosphorus ﬁnal concentration, with low trace element
casein (Avicel PH-101 Cellulose). Diets and water were introduced at wean-
ing (age 4 wk) and were provided ad libitum throughout the study.
Serum Biochemistries. Blood samples were collected by tail bleed according to
approved protocols or by cardiac puncture when mice were killed. Routine
serum biochemistries were determined by standard automated methods:
Calcium (Ca), phosphate (Pi), alkaline phosphatase (AP), creatinine (Cr), and
total serum iron (Fe) were measured using a COBAS MIRA Plus Chemistry
Analyzer (Roche Diagnostics). Serum 1,25(OH)2 vitamin D was measured
using an enzyme immunoassay (Immunodiagnostic Systems), and PTH was
measured with a mouse intact PTH Kit (Immutopics International), according
to the manufacturers’ instructions. A mouse CBC was performed on whole
blood using a Mascot HemaVet950FS automated processor.
Serum Fgf23 Measurements. Serum intact Fgf23 concentrations were assessed
using a commercial ELISA according to the manufacturer’s protocol (Kainos
Laboratories Inc.). This two-site, monoclonal antibody ELISA has been shown
previously to recognize rodent Fgf23. Serum Fgf23 also was measured using
a rodent-speciﬁc C-terminal Fgf23 ELISA with capture and detection anti-
bodies that bind to rodent Fgf23 protein 3′ C-terminal to the 176RXXR179/S180
SPC site, according to the manufacturer’s speciﬁcations (Immutopics In-
ternational). For the rodent-speciﬁc C-terminal Fgf23 kit, anti-peptide poly-
clonal antibodies were derived as follows: The capture antibodies recognize
epitopes within mouse Fgf23 residues 186–206, and the detection antibodies
recognize epitopes within mouse FGF23 residues 225–244.
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Histology and Immunoﬂuorescence. After animals were killed, the kidneys and
femur were removed and dissected free of connective tissue. Kidneys were
prepared as previously described (19). Sections were probed with anti-mouse
Npt2a (1:300; generous gift of Heini Murer, Jürg Biber, and Nati Hernando
of the Institute of Physiology, University Zürich, Zurich), anti-mouse Klotho
(1:5; Santa Cruz Biotechnology), anti–p-ERK1/2 (1:50; Cell Signaling Tech-
nology), or anti-Nherf1 (1:50; Sigma) followed by incubation with anti-rabbit
and anti-rat (1:200) ﬂuorescent secondary antibodies (Alexa Fluor; Invi-
trogen, Inc.). Slides were mounted in the presence of DAPI (Vector Labora-
tories) and were imaged with the same setting across groups using a Leica
DM5000B ﬂuorescent microscope (Leica Microsystems, Inc.) with a SPOT
camera and analysis software (Diagnostic Instruments).
Femurs were removed and ﬁxed in 4% paraformaldehyde. The distal
femurs were embedded in methyl methacrylate, and midsagittal (4-μm)
sections of cancellous bone from the distal femur were cut using a micro-
tome (2050 Supercut; Reichert-Jung). The sections were treated with Gold-
ner’s stain according to established protocols and were examined blinded to
mouse diet and genotype. Histomorphometric measures were obtained at
the distal femur metaphysis using standard protocols (45) and a semi-
automatic analysis system (Bioquant OSTEO; Bioquant Image Analysis Co.)
attached to a Nikon microscope. A deﬁned region of interest (∼0.5 mm from
the growth plate and encompassing 3–4 mm2) was used to determine bone
surface, osteoid surface, and osteoid thickness. The terminology and units
used are those recommended by the Histomorphometry Nomenclature
Committee of the American Society for Bone and Mineral Research (46).
RNA Preparation and Quantitative RT-PCR. Kidney, liver, and bone were har-
vested and homogenized in 1 mL of TRIzol reagent (Invitrogen, Inc.) according
to the manufacturer’s protocol using a TissueTearor rotor-stator (Biospec
Products, Inc.). Total RNA from UMR-106 cellular lysates was prepared using
the RNeasy Kit (Qiagen, Inc.). RNA samples were tested with intron-spanning
primers speciﬁc for mouse vitamin D 24-hydroxylase (Cyp24), mouse vitamin D
1-α-hydroxylase (Cyp27b1), mouse and rat Fgf23, mouse Hamp, and rat
TfRc1. Mouse or rat β-actin was used as an internal control. All qPCR primers
and probes were purchased as preoptimized reagents (Applied Biosystems,
Inc.) or were produced in-house, and sequences are available upon request.
The TaqMan One-Step RT-PCR kit was used to perform qPCR. PCR con-
ditions for all experiments were 30 min at 48 °C, 10 min at 95 °C, followed by
40 cycles of 15 s at 95 °C and 1 min at 60 °C. The data were collected and
analyzed by the 7500 Real Time PCR system and software (Applied Bio-
systems). All primer sets were tested for speciﬁc ampliﬁcation of mRNA by
parallel analyses of controls that included omitting RT or template and
resulted in no ﬂuorescent signal detection. Each RNA sample was analyzed
in at least triplicate, and each in vitro experiment was performed in-
dependently at least three times. The 2-∆∆CT method described by Livak and
Schmittgen (47) was used to analyze the data.
Cell Culture. UMR-106 cells (American Type Culture Collection) were cultured
in D-MEM/F-12 (Invitrogen) supplemented with 10% FBS (HyClone; Thermo-
Fisher, Inc.) and 25 mM penicillin-streptomycin at 37 °C and 5% CO2. For
bioactivity assays, cells (1.5 × 105) were seeded in 24-well plates. Cells were
iron depleted with the iron chelator DFO (25–50 μM) for 24–48 h. These DFO
concentrations are within a range known to have biological effects in UMR-
106 cells (21, 22). Cells also were pretreated with actinomycin D as speciﬁed.
To test Mapk signaling, cells were pretreated with the MEK inhibitor U0126
(10 μM) 1 h before DFO addition. The EGLN inhibitor L-mimosine (25–100
μM) was used to activate HIFs.
Western Blot Analysis. UMR-106 cells were lysed with 100 μL 1× Lysis buffer
(Cell Signaling Technologies, Inc.) with 1 μg/mL 4-(2-aminomethyl)benzene-
sulfonyl ﬂuoride hydrochloride (AEBSF) protease inhibitor (Sigma-Aldrich,
Inc.). Cell lysate protein concentrations were determined with the Better
Bradford Kit (Thermo-Fisher Scientiﬁc) according to the manufacturer’s
instructions. Western blot analysis was performed as previously described
(48) with 50 μg UMR-106 cellular lysates. The blots were incubated with
primary antibodies [anti–p-ERK1/2 (Cell Signaling Technologies, Inc.); anti–
total-ERK (Promega); anti-HIF1α (NB100-134), and anti-HIF2α (NB100-122)
(Novus Biologicals)] and then were incubated with the appropriate sec-
ondary antibody at 1:3,000 [anti–rabbit-HRP (Bio-Rad, Inc.)] at 1:3,000. De-
tection was performed using the ECL Plus Western Blotting Detection
Reagents (Amersham-GE Healthcare) and X-Omat ﬁlm (Eastman-Kodak Co.).
Fgf23 Immunoprecipitation. Femurs and tibias from treatedmicewere cleaned
of connective tissue and homogenized in 1 mL 1× lysis buffer (Cell Signaling
Technologies, Inc.) with 1 μg/mL AEBSF. The solid particles were removed by
centrifugation at 15,000 × g at 4 °C, and the supernatant was stored at −80 °C
until use. Fgf23 was precipitated from 1,600 mg/mL of bone lysate with 125
ng of the goat anti-mouse Fgf23 capture and detection antibodies from the
C-terminal mouse Fgf23 ELISA Kit (see above; puriﬁed antibodies were
generous gifts of Immutopics International, Inc.) for 4 h at room tempera-
ture. The IgG complexes were captured using Protein A&G resin binding
(Pierce, Inc.) and washed three times in 1× lysis buffer. The precipitants were
solubilized in 2× Leammli sample buffer (Bio-Rad, Inc.) at 95 °C before gel
electrophoresis and Western blotting, which were performed as outlined
above. The Western blots of precipitated Fgf23 were incubated with the
detection antibody from the mouse C-terminal Fgf23 ELISA, a biotin-conju-
gated anti-mouse Fgf23 (2 μg/mL; generous gift of Immutopics International),
followed by incubation with avidin-HRP (1:1,000; Bio-Rad, Inc.) and ECL de-
tection. Anti-actin (1:1,000; Santa Cruz Biotechnology, Inc.) was used as the
internal lysate control for gel loading.
Statistical Analysis. All analyses were performed separately for male and
female mice, and if there was no interaction between the primary predictor
variable and sex, the datawere combined, and sexwas included as a covariate
when appropriate. Subsequent analyses were performed for each outcome of
interest including serum biochemistries and expression levels of key genes,
log-transformed to normalize the distribution if necessary. Two-way ANOVA
was used to test for genotype–diet interaction at each time point on each
outcome, assuming unequal within-group variances for expression data.
Repeated-measures ANOVA was used to test for between-group differences
in serial FGF23 measurements. Signiﬁcance interactions were followed by
pairwise comparisons between diets within genotype using t tests except for
FGF23 measurements with extreme bimodal distributions at weeks 6 and 8.
In the latter case the outcome was dichotomized into abnormally high (>2.5
SD above the mean of the WT mice on control diet) or not abnormally high,
and Fisher’s exact test was used to test for differences in proportions be-
tween groups. Data are presented as SEM.
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Fig. S1. Gene targeting for development of an autosomal dominant hypophosphatemic rickets (ADHR) mouse carrying the R176Q-ﬁbroblast growth factor 23
(Fgf23) allele. (A) (Left) Targeting strategy for the mouse R176Q-Fgf23 ADHR allele. The R176Q ADHR mutation was introduced (triangle) into exon 3 of the
mouse Fgf23 gene. A ﬂoxed-neomycin resistance gene (Neor) cassette was placed into intron 2, and a silent SacI site was introduced into exon three, 3′ to the
R176Q mutation. (Right) Southern analyses with SacI digests on DNA lysates from ES cells and a 3′ external probe detected the R176Q-ADHR allele as a 5-kb
band, in contrast to the 10-kb WT band. Het, ADHR heterozygous R176Q cells; WT, homozygous wild-type cells. Offspring from founder mice were positive for
the ﬂoxed-Neor cassette. (B) The LoxP-Neor cassette in the R176Q-ADHR allele was removed by breeding to an EIIa-Cre transgenic mouse as shown by PCR
analyses within intron 2. A slightly larger PCR product in the Het mice contained the LoxP site that remained following Cre-mediated recombination. (C)
Sequence analysis of Fgf23 RT-PCR products from heterozygous ADHR mouse bone mRNA demonstrated properly spliced ADHR-mutant and WT Fgf23 mRNAs
(WT codon: cgc; ADHR codon: cag, arrows). The R(Q)176HTR179/S180 protein sequence comprising the Fgf23 SPC site is shown above the sequence traces for
orientation.
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Table S1. Complete blood cell counts in WT and ADHR mice
Genotype and
diet
Mean corpuscular
volume (fL)
Mean corpuscular
hemoglobin (pg)
Hemoglobin
(g/dL) Hematocrit (%)
Red blood cell
distribution width (%) Red blood cells (M/μL)
WT control diet 46.1 ± 0.68 14.4 ± 0.17 10.2 ± 1.0 32.9 ± 3.19 18.3 ± 0.87 7.1 ± 0.65
WT low-iron diet 38.4 ± 1.20* 10.1 ± 0.16* 7.1 ± 0.68† 27.2 ± 2.87 28.7 ± 1.86† 6.99 ± 0.65
ADHR control diet 45.7 ± 0.56 14.7 ± 0.38 9.5 ± 0.96 29.4 ± 2.81 16.84 ± 0.36 6.44 ± 0.63
ADHR low-iron diet 35.8 ± 1.07* 11.3 ± 0.37* 6.9 ± 0.97‡ 21.8 ± 2.99 22.2 ± 1.35‡ 6.04 ± 0.78
n = 9–11 mice per cohort.
*P < 0.001.
†P < 0.05.
‡P < 0.08.
Table S2. Biochemistries for heterozygous ADHR mice
Biochemistry Control diet 8 wk Low-iron diet 8 wk Control diet 12 wk Low-iron diet 12 wk
Intact Fgf23 (pg/mL) 135.4 ± 9.1 86.9 ± 8.3* 123.3 ± 14.0 71.8 ± 15.0*
C-terminal Fgf23 (pg/mL) 356.0 ± 19.5 1297.1 ± 264.2† 327.8 ± 28.0 1687.6 ± 286.0†
Serum phosphorus (mg/dL) 10.3 ± 0.27 8.75 ± 0.38* 10.19 ± 0.37 8.49 ± 0.25*
Serum calcium (mg/dL) 10.1 ± 0.10 10.25 ± 0.10 10.3 ± 0.18 10.3 ± 0.12
Alkaline phosphatase (U/L) 116.1 ± 6.1 136.5 ± 9.1* 100.9 ± 8.6 108.1 ± 5.2
Serum creatinine (mg/dL) 0.34 ± 0.03 0.34 ± 0.04 0.36 ± 0.04 0.37 ± 0.04
n = 11–23 mice per cohort.
*P < 0.01.
†P < 0.0001.
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